WHITEOAK CAPITAL MANAGEMENT
THE ART AND SCIENCE OF INVESTING

Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Viyash Scientific Ltd (Previously known as Sequent Scientific Limited)		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	White Oak Capital Management Consultants LLP on behalf of Funds/ SMA Managed/ Advised **(Please refer Annexure 1 for details)**		
Whether the acquirer belongs to Promoter/ Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	National Stock Exchange of India Limited and Bombay Stock Exchange Ltd		
Details of the ~~acquisition~~/ disposal as follows	Number	% w.r.t total share/ voting capital wherever applicable (*)	% w.r.t total diluted share/ voting capital of the TC (**)
Before the ~~acquisition~~/disposal under consideration, holding of :			
a) Shares carrying voting rights	**9,353,641*** **	**2.14%*** **	**1.95%*** **
b) Shares in the nature of encumbrance (pledge/ lien/ non -disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/ Convertible securities/ any other instrument that entities the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	**9,353,641*** **	**2.14%*** **	**1.95%*** **
Details of ~~acquisition~~/ sale			
a) Shares carrying voting rights ~~acquired~~ /sold	**8,747,392**	**2.00%**	**1.82%**
b) VRs ~~acquired~~/ sold otherwise than by shares	-	-	-
c) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) ~~acquired~~/ sold	-	-	-
d) Shares encumbered/invoked/released by the acquirer	-	-	-
e) Total (a+b+c+d)	**8,747,392**	**2.00%**	**1.82%**
After the ~~acquisition~~/ sale, holding of:			
a) Shares carrying voting rights	**606,249**	**0.14%**	**0.13%**
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	**606,249**	**0.14%**	**0.13%**
Mode of ~~acquisition~~ / sale (e.g. open market/ off-	Open market		

market/ public issue/ rights issue/ preferential allotment/ inter-se transfer etc.)	
Date of ~~acquisition~~ of / sale of shares / VR or date of receipt of intimation of allotment of shares whichever is applicable	October 15, 2026
Equity share capital / total voting capital of the TC before the said ~~acquisition~~ / sale	436,875,477 equity shares having Face value of Rs. 2 each
Equity share capital/ total voting capital of the TC after the said ~~acquisition~~ / sale	436,875,477 equity shares having Face value of Rs. 2 each
Total diluted share/voting capital of the TC after the said ~~acquisition~~ / sale	479,928,915 equity shares having Face value of Rs. 2 each

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/ voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/ warrants into equity shares of the TC.

(***) As per **Regulation 29(1)** of SEBI (SAST) Regulations 2011, we had made a disclosure of total of holding **1,24,47,490 shares** in Sequent Scientific Ltd (currently known as Viyash Scientific Ltd), which was equivalent to **5.01 %** of the company's issued shares on account of **purchases/ acquisition** made in various funds managed/advised by WO Capital on **March 16, 2022**. Further, pursuant to execution of Business Transfer Agreement, there was transfer of Portfolio Management Business ('PMS') from WO Capital to WhiteOak Capital Asset Management Limited with effect from **01st April 2024.** Hence, the revised threshold in WO Capital post transfer of **PMS (1.25%)** stood at **3.77%.**

Pursuant to scheme of amalgamation, Sequent Scientific Ltd **("Sequent")** has allotted shares to shareholders of Viyash Life Sciences Private Limited **("Viyash")** in the share exchange ratio of **56:100** i.e., 56 fully paid-up equity shares of Sequent of the face value of INR 2/- (Indian Rupees Two only), for every 100 fully paid-up equity shares of Viyash of INR 10 (Indian Rupees Ten only). Consequent to such allotment, the existing holding of WO Capital i.e. **3.77%** of total share capital of Target Company (Pre-amalgamation) is now **2.14%** of the total share capital of the Target Company (Post-amalgamation).

Accordingly, the aforesaid reporting is done as per Regulation 29(2) of SEBI (SAST) Regulations, 2011.

RIDDHI MAHESHBHAI GOHEL

Digitally signed by RIDDHI MAHESHBHAI GOHEL
Date: 2026.10.16 16:57:54 +05'30'

Riddhi Gohel
Authorised Signatory

Place: Mumbai
Date: October 16, 2026

WHITEOAK
CAPITAL MANAGEMENT
THE ART AND SCIENCE OF INVESTING

Annexure 1

List of Funds/Separate Managed Accounts (SMA) Managed/Advised by White Oak Capital Management Consultants LLP (India) and Ashoka WhiteOak Capital Pte. Ltd. (Singapore) and Acorn Asset Management Ltd *

Sr. No.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer (Fund/SMA)
1	DENDANA INVESTMENTS (MAURITIUS) LIMITED
2	Ashoka India Equity Investment Trust Plc
3	India Acorn Fund

* White Oak Capital Management Consultants LLP (WO India) and Ashoka WhiteOak Capital Pte. Ltd. (WO Singapore) and Acorn Asset Management Ltd (WO Mauritius) have a common promoter and WO India provides advisory services to WO Singapore and WO Mauritius for all Funds/SMA for whom WO Singapore and WO Mauritius is the Investment Manager.